Start here if you're new
what it is
It engineers bacteria into six drug candidates for rare metabolic and immune diseases.
how it gets paid
Last year Synlogic made $0 in revenue.
why growth slowed
Revenue fell 100.0% last year. The latest quarter showed no sales and a $0.20 loss per share.
what just happened
Revenue was $0, and EPS was -$0.20.
At a glance
C+ balance sheet — struggling to keep the lights on
20/100 earnings predictability — expect surprises
3.5x trailing p/e — the market's not buying it — or you found a deal
-$0.29 fy2024 eps est
$2B fy2026 rev est
xvary composite: 28/100 — weak
What they do
It engineers bacteria into six drug candidates for rare metabolic and immune diseases.
You are not buying sales. You are buying six pipeline shots, including SYNB1934 in Phase III and SYNB1353 and SYNB8802 in Phase II. Phase III means late-stage human testing, and revenue is $0. That makes trial data the whole pitch.
How they make money
$0
annual revenue · revenue declined -100.0% last year
The products that matter
corporate entity only
Public Shell
119M shares outstanding
this is the thing you actually own now: a listed legal entity with 119M shares and no operating business attached to it.
what remains
discontinued drug programs
Legacy Clinical Pipeline
$0 revenue
the old biotech story ended. the pipeline is shut down, which is why reported revenue is $0 and why conventional biotech comps stop helping you.
story ended
listing and reporting status
Nasdaq Suspension
jan 21, 2026
trading was suspended on Jan. 21, 2026. from here, filings matter more than product milestones because there are no product milestones left.
liquidity risk
Key numbers
$7M
market cap
You are paying $7M for a company with $0 revenue. That is the whole setup.
$0
annual revenue
No sales means the stock depends on trial data and cash.
1.2
beta
Beta → how wild the stock is → 1.2 means a bit more swing than the market.
5/100
price stability
Price stability → how smooth the chart is → 5/100 says the tape can lurch.
Financial health
C+
strength
- balance sheet grade C+ — weak — may struggle to fund operations
- risk rank 5 — safer than 5% of stocks
- price stability 5 / 100
C+ — below average. watch for debt servicing and cash burn.
Total return vs. market
Return history isn't available for SYBX right now.
source: institutional data · return history unavailable
What just happened
missed estimates
Revenue was $0, and EPS was -$0.20.
The latest quarter showed no sales and a $0.20 loss per share. Annual revenue was also $0, so the business is still a clinical story, not a cash story.
$0
revenue
-$0.20
eps
n/a
n/a
the number that mattered
The number that mattered was $0 revenue. That leaves you with trials, dilution, and survival.
source: EDGAR SEC filing, latest quarter
Get this snapshot in your inbox
This page, delivered free — plus weekly updates when the numbers change. plain english, no spam.
weekly updates
earnings alerts
plain english
no spam
What could go wrong
the #1 risk is Nasdaq suspension turning this into a liquidity trap.
med
Liquidity can disappear faster than the thesis
Nasdaq suspended trading on Jan. 21, 2026. Once a stock stops trading normally, your ability to exit becomes part of the risk case, not an afterthought.
Impact: price discovery weakens and any quote can become less actionable than it looks.
med
There is no operating business to re-rate
Reported revenue is $0 and the clinical pipeline is gone. That means there is no sales recovery, margin story, or product launch waiting to rescue the thesis.
Impact: without a new transaction, the shares are tied to shell value, not fundamentals.
med
Corporate outcome risk is binary
A shell can liquidate, merge, find a new business, or just linger. Those paths create wildly different outcomes, and the filings do not give you a clean probability distribution.
Impact: you can be directionally right that "something happens" and still be wrong on value.
med
The data itself can mislead you
This page still contains a 3.5x trailing p/e, a $2B FY2026 revenue estimate, a $1.16 quote, a $7M market cap, and 119M shares that do not cleanly fit together. That is what stale or broken market plumbing looks like.
Impact: screen-based investors can mistake bad inputs for cheapness.
A $7M shell with $0 revenue and 119M shares can stay unresolved longer than you want, and the lack of clean market data makes fake precision especially dangerous.
source: institutional data · regulatory filings · risk analysis
Pay attention to
next date
march 17 filing
The next confirmed earnings release is scheduled for March 17, 2026. For you, that filing is the closest thing to an operating update this company still has.
data quality
price, market cap, and share count reconciliation
The quoted $1.16 price, $7M market cap, and 119M shares do not line up cleanly. If that mismatch gets resolved, you will have a clearer sense of what the market is actually pricing.
corporate path
any merger, liquidation, or reverse-merger language
There is no operating moat to monitor. The real catalyst list is corporate: asset sale, cash distribution, new business combination, or formal wind-down.
listing status
whether the suspension leads to a permanent dead end
A suspended listing can become an extended limbo state. The longer that lasts, the less useful normal market signals become for your decision-making.
Analyst rankings
earnings predictability
20 / 100
in human-speak, the published earnings metrics are not something you should trust much here.
risk rank
5
safer than 5% of stocks means riskier than 95% of them. that fits a suspended shell.
price stability
5 / 100
the market is telling you this is not a steady asset. it trades like uncertainty because uncertainty is the business model now.
source: institutional data
Institutional activity
institutional ownership data for SYBX is being compiled.
source: institutional data
Price targets
3-5 year target range
n/a
n/a
$1
current price
n/a
target midpoint · n/a from current
Want the deeper analysis?
The full deep dive: dcf model, scenario analysis, competitive moat breakdown, and quarterly tracking — everything on this page, taken further.
see plans from $5/moThe deep dive